A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer

Recruiting now · Early Phase 1

Conditions studied: High-risk Prostate Cancer

In brief

This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of epigenetic therapies in participants with localized prostate cancer who are undergoing radical prostatectomy. The epigenetic therapy is intended to increase the sensitivity of the underlying tumor to the patient's immune system. The platform study will evaluate safety, biomarkers, and clinical activity of an epigenetic therapy. The particular details relevant to each module within this platform study will be provided as appendices to the core protocol.

Key facts

Study ID

NCT06888102

Run by

Edwin Posadas, MD

People needed

20

Starts

2026-04-01

Expected to finish

2029-10-01

Last updated by the study team

2026-02-03

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men electing to undergo radical prostatectomy with preoperative tissue available.
• Age ≥18 years
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
• Adequate organ function defined by:
• AST and ALT < 2.5 x ULN
• Total bilirubin < 1.5 x ULN
• Platelets > 90 x 1000/μL
• Hemoglobin (Hgb) > 8.5 g/dL
• Serum Creatinine (Cr) <1.5 x ULN or eGFR > 30 mL/min
• People with partners of childbearing potential in circumstances that may result in the pregnancy, must have had a successful vasectomy (with medically confirmed lack of sperm that are alive) OR must either practice complete abstinence or agree to use adequate contraception (latex or synthetic condom during sexual contact with a female of childbearing potential) from the start of study treatment until 3 months following last dose of study intervention. Subjects should not donate sperm on study, during interruptions in treatment and for 3 months following completion of study drug treatment.
• Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.

You may not qualify if…

• Active intercurrent illness or malignancy requiring therapy outside of prostate cancer.
• Other anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization)
• Currently participating in a study using an investigational, medicinal anti-cancer agent within 4 weeks prior to first dose of epigenetic therapy.

Where it is running

• Cedars-Sinai Cancer at SOCC — Los Angeles, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.